Clinical trials: Liver Tumour
Hepatocellular Carcinoma, Liver Cirrhosis
Sonazoid Enhanced Liver Cancer Trial for Early Detection
The aim of this study is to prove usefulness of contrast-enhanced ultrasound (CE-US) using Sonazoid (TM) in the early detection of HCC as compared with conventional B-mode ultrasound (B-mode US) for hepatitis virus related…
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Hepatitis B, Hepatitis C
- Trial name
- NCT00822991
- Testing
- CE-US (Sonazoid™), B-mode US
- Where
- Japan
- Volunteers
- 760 people
- Sponsor
- Kindai University
Uveal Melanoma, Metastatic Cancer
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
Phase II clinical trial aimed to evaluate the efficacy of the combination of cediranib and durvalumab in patients with metastatic uveal melanoma (mUM) with biopsiable disease at first line of after failure to first line systemic…
- Trial name
- CEDUVEAL-M (NCT04184518)
- Testing
- Cediranib Maleate, Durvalumab
- Where
- 5 sites in Spain
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Hepatocellular Carcinoma
Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma
Chiauranib, which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
- Trial name
- NCT03245190
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Hepatocellular Carcinoma
Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Hepatocellular carcinoma (HCC) is a common disease with high mortality. More than 80% patients receive a diagnosis when their tumors are too advanced for curative approaches and have a dismal prognosis.
- Trial name
- NCT04011033
- Testing
- iNKT cells, Human recombinated Interleukin-2, TAE/TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing YouAn Hospital
Carcinoma, Hepatocellular, Colorectal Neoplasms
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
This study will follow-up immune cell populations, secreted factors and released nanovesicles in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of the…
- Conditions
- Carcinoma, Hepatocellular, Colorectal Neoplasms, Melanoma, Kidney Neoplasms
- Trial name
- NCT02439008
- Testing
- Blood samples collection before radiotherapy, Blood samples collection during radiotherapy, Blood samples collection after radiotherapy
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Oscar Lambret
Intrahepatic Cholangiocarcinoma, Liver Tumor
Treat Primary and Metastatic Liver Tumors
The use of Radiospheres in the management of intrahepatic cholangiocarcinoma is largely unknown and not reported in the medical literature.
- Conditions
- Intrahepatic Cholangiocarcinoma, Liver Tumor, Metastatic Cancer, Metastatic Liver Cancer
- Trial name
- NCT05240040
- Sponsor
- Methodist Health System
Liver Tumors
Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration
The goal of this research study is to find out if using an updated version of standard computer software (called RayStation) for confirming that thermal ablation treatment was able to destroy all tumor cells including a safety…
- Trial name
- NCT07877220
- Testing
- RayAblation
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma (HCC), TACE
DEB-TACE vs cTACE in HCC After TIPS
This is a Phase 3, open-label, multicenter, randomized controlled clinical trial designed to evaluate the efficacy and safety of Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) compared with Conventional…
- Conditions
- Hepatocellular Carcinoma (HCC), TACE, TIPS, DEB-TACE
- Trial name
- UPGRADE (NCT07322848)
- Testing
- DEB-TACE, cTACE
- Where
- China
- Volunteers
- 206 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Liver Cirrhosis, Liver Neoplasms
Parenchyma Resection of Cirrhotic Liver by the Clamp Crushing Technique and the Ultrasonic Dissector
To identify the most efficient parenchyma transection technique for cirrhotic liver resection between the clamp crushing technique and the ultrasonic dissector.
- Conditions
- Liver Cirrhosis, Liver Neoplasms, Carcinoma, Hepatocellular
- Trial name
- SECCI (NCT00763776)
- Testing
- clamp crushing technique, ultrasonic dissector
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer, Liver Metastases
Clinical, Histological and In-depth Molecular Characterization as Well as Experimental Models of Liver Metastasis From Patients With Breast Cancer in Order to Identify New Potential Treatment Avenues.
The goal of this observational study is to learn about breast cancer liver metastasis in patients who met the following criteria: female; be ≥ 18 years of age on the day of signing informed consent; confirmed diagnosis of breast…
- Trial name
- OLiver Pro (NCT05720676)
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- KU Leuven
Oncology
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
The primary objective of this study is to evaluate the pharmacokinetics of entospletinib (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function (stratified by smoking status, as appropriate)…
- Trial name
- NCT02521376
- Testing
- Entospletinib
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic, Hepatocellular Carcinoma
Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
The current first-line treatment for HBV is long-term oral antiviral drugs to inhibit HBV DNA replication. First-line antiviral drugs recommended by the Chinese 2015 Hepatitis B Guidelines include ETV and TDF.
- Conditions
- Hepatitis B, Chronic, Hepatocellular Carcinoma, Compensated Cirrhosis
- Trial name
- NCT04160897
- Testing
- Entecavir, Tenofovir Disoproxil
- Where
- China
- Volunteers
- 4,000 people
- Sponsor
- Qing XIe
Lung Cancer, Liver Cancer
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or…
- Conditions
- Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05187338
- Testing
- ipilimumab +pembrolizumab +durvalumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
PHENYTOIN/SORAFENIB [VA Drug Interaction], Liver Neoplasms
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the hypoxia caused by TACE in surviving tumor cell leads to release of angiogenic and growth factors contributing to…
- Conditions
- PHENYTOIN/SORAFENIB [VA Drug Interaction], Liver Neoplasms, Carcinoma, Hepatocellular, Digestive System Neoplasms
- Trial name
- NCT01556815
- Testing
- Transarterial Chemoembolization (TACE), Sorafenib in combination with TACE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shandong Cancer Hospital and Institute
Gastrointestinal Cancer, Liver Cancer
Collecting Solid Tumor Tissue to Identify New Treatments
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells…
- Conditions
- Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer, Melanoma
- Trial name
- NCT01658917
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma Non-Resectable
Y-90 SIRT for Unresectable HCC Larger Than 7cm
This is a phase II clinical study to evaluate the efficacy and safety of SIRT in patients with HCC greater than 7 cm. After enrollment, patients received yttrium-90 selective internal radiation therapy.
- Trial name
- NCT06707233
- Testing
- SIRT
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Pancreatic Cancer
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study
Patients with PCLM account for the majority of our department's pancreatic cancer cases and often have limited surgical options due to the aggressive nature of their tumors.
- Trial name
- NCT06404840
- Testing
- nimotuzumab, AG chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatitis C, Breast Cancer
Hepatitis C Screening Paired With Mammography
In France, a breast cancer screening is organized since 2004 for women aged 50-74. On the other hand, even though the seroprevalence of hepatitis C in the general French population is less than 1%, it is estimated that more than…
- Trial name
- Mammo'C (NCT05067374)
- Where
- 4 sites in France
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Liver Cirrhosis, Hepatocellular Carcinoma
Boramae Hospital Liver Cirrhosis Patient Cohort Study
Liver cirrhosis represents a worldwide health problem and is a major cause of mortality. Cirrhosis is the common end for chronic alcohol abuse and hepatitis C and B virus infections.
- Trial name
- NCT01943318
- Testing
- Liver biopsy, Hepatic venous pressure gradient (HVPG) measurement
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Seoul National University Boramae Hospital
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary…
- Trial name
- NCT07368023
- Testing
- Locoregional Therapy (LRT) + Systemic Drug Therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.